NCT04780334 (COR-DIAL-S) is a clinical trial of COVID-19 RT-PCR in SARS-CoV Infection, sponsored by University Hospital, Lille.

Who is sponsoring NCT04780334?

NCT04780334 is sponsored by University Hospital, Lille.

What drugs are being tested in NCT04780334?

Interventions in NCT04780334: COVID-19 RT-PCR, Biosensor.

What condition does NCT04780334 study?

NCT04780334 studies SARS-CoV Infection, Covid19.

Is NCT04780334 still recruiting?

NCT04780334 is currently completed. Last updated 13 December 2024.

Last reviewed 2024-12-13 · How we verify

NCT04780334: COR-DIAL-S

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

Completed Last updated 13 December 2024

What this trial tests

trial testing COVID-19 RT-PCR in SARS-CoV Infection in 200 participants. Completed in 2 May 2022.

Timeline

7 July 2021

Primary endpoint
2 May 2022

2 May 2022

Quick facts

Lead sponsor	University Hospital, Lille
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	7 July 2021
Primary completion	2 May 2022
Estimated completion	2 May 2022
Sites	1 location across France

Drugs / interventions tested

COVID-19 RT-PCR
Biosensor

Conditions studied

SARS-CoV Infection — all drugs for SARS-CoV Infection →
Covid19 — all drugs for Covid19 →

Sponsor

University Hospital, Lille

Who can join

Eligibility, any sex, with SARS-CoV Infection or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this CorDial-S proof-of-concept study is to evaluate the ability to detect COVID-19 infection in nasopharyngeal swabs with CorDial-S and compare it to the PCR technique currently in use. Saliva analysis will be the subject of secondary analysis. The CorDial-S medical device could allow the specimens to be analyzed using a small portable device and the results to be returned in minutes to the medical team and the patient, and communicated in real time with a telemedicine and remote monitoring system to the health authorities to allow the necessary protective, containment and therapeutic management measures to be put in place if necessary. The benefits would be 1. greater sensitivity 2. a great speed because 8tests could be performed at the same time with a result in a few minutes 3. a very high specificity at least equivalent to PCR. This new diagnostic strategy could become extremely valuable in the fight against COVID-19, especially in the case of very long-term persistence and incomplete vaccination of the French and foreign population.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SARS-CoV-2 detection using a nanobody-functionalized voltammetric device.
Pagneux Q, Roussel A, Saada H, Cambillau C, et al · · 2022 · cited 16× · PMID 35619829 · DOI 10.1038/s43856-022-00113-8
Plasmonic Approaches for the Detection of SARS-CoV-2 Viral Particles.
Szunerits S, Saada H, Pagneux Q, Boukherroub R. · · 2022 · cited 7× · PMID 35884352 · DOI 10.3390/bios12070548

Verify or expand the search:

Other trials of COVID-19 RT-PCR

Trials testing the same drug.

NCT04367142 — Rapid Detection of COVID-19 by Portable and Connected Biosensor · completed
NCT04348422 — Evaluating the Immune Response for COVID-19 · completed
NCT04368338 — Lung Ultrasound to Diagnose COVID-19 · completed

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

NCT05886816 — Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 · Phase 2 · recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
NCT04579471 — Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study · recruiting

Other University Hospital, Lille trials

Trials by the same sponsor.

NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04780334 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
Last refreshed: 13 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing